Immunicom Hosts 1st Annual Global Immunopheresis Conference

This event provided a forum for oncology clinical leaders to meet, discuss and learn about Immunicom's novel, cutting-edge immunotherapy − Immunopheresis™. The conference was a collaborative event involving Immunicom's global partners and focused on therapeutic apheresis as a viable clinical approach in oncology that potentially represents a less-costly innovation than currently-available therapies with the promise to enhance patient care and quality of life.

Immunicom Secures

$11 Million in Series B Investment Round

 Immunicom raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million."Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom's global strategic partnerships," said Amir Jafri, the company's Founder and CEO.

Immunotherapy Product Receives F.D.A. Breakthrough Device Designation

Immunicom has achieved Breakthrough Device designation!  To achieve Breakthrough Device designation, a technology must demonstrate compelling potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.  In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives 

Immunicom CEO Featured in Fireside Chat with U.S. Rep. Dan Crenshaw, Following Speech by Nobel Laureate James Allison

March

2020

Amir Jafri, CEO and Founder, was one of five exclusively invited guest panelists at Congressman Dan Crenshaw's second annual Healthcare Innovation Summit held at Rice University!

Immunicom CEO Leads Impactful & Important Roundtable & Panel Discussion with Key Industry Innovators at the C3 US-Arab Healthcare Business Summit in NYC

October

2019

Amir Jafri, CEO and Founder, moderated two roundtables and a panel discussion on innovation in healthcare at the annual  C3 US-Arab Healthcare & Business Summit

Immunicom Secures an Additional $1.85 Million Bringing in Series B Funding to $12.85 Million

September

2019

Immunicom gained an additional $1.85 million towards Series B investment round. This increases Immunicom's overall capital raised to $21.85 million.

Immunicom hires Raju Chauhan as Vice President of Program Management

September

2019

With over 30 years of experience managing teams across the globe, Immunicom is excited to add Raju Chauhan to the team. 

Immunicom hosts 1st Annual Global Immunopheresis Conference in Krakow, Poland

July - August

2019

This event provided a forum for oncology clinical leaders to meet, discuss and learn about Immunicom's novel, cutting-edge immunotherapy − Immunopheresis™. The conference was a collaborative event involving Immunicom's global partners and focused on therapeutic apheresis as a viable clinical approach in oncology that potentially represents a less-costly innovation than currently-available therapies with the promise to enhance patient care and quality of life.

Immunicom Secures $11 Million in Series B Investment Round

July

2019

 Immunicom raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million."Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom's global strategic partnerships," said Amir Jafri, the company's Founder and CEO.

First Patient Enrollment in Mutli-Center Triple Negative Breast Cancer Clinical Trial

June

2019

This randomized, multi-center, TNBC clinical study compares Immunopheresis™ alone and its use in combination with low-dose paclitaxel and carboplatin weekly chemotherapy, versus a control arm of low-dose chemotherapy.  Immunicom's Immunopheresis therapy is a revolutionary new non-drug, blood-filtering immunotherapy treatment, with the potential to effectively treat a wide variety of cancer types more effectively and with fewer side effects, including those that have failed response to other treatment approaches. 

01/

Immunotherapy Product Receives F.D.A Breakthrough Device Designation

02/

Journal of Translation Medicine: "Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic

03/

Immunicom's Secures

$11 Million in Series B Investment Round

04/

First Patient Enrollment in Multi-Center  Triple Negative Breast Cancer Clinical Trial

Immunicom expands relationship with Terumo BCT, to support collaboration with CHIPSA oncology hospital

December

2017

Immunicom is excited to collaborate with CHIPSA oncology hospital to begin human clinical trials. Additionally, Immunicom's growing relation with Terumo BTC allows for more extensive research and development of the device. 

David Schlotterbeck, former Vice Chairman of Cardinal Health, joins Immunicom's Board of Directors as Chairman of the Board

September

2017

Immunicom is excited to welcome David Schlotterbeck -  a technology leader with over 45 years of healthcare experience. 

Amir Jafri, President and CEO of Immunicom, presents during the 35th Annual J.P. Morgan Healthcare Conference

January

2017

With over 10,000 attendees and over 450 public and private companies, the annual J.P. Morgan Healthcare Conference is one of the largest healthcare investment conferences in the industry.

​Dr. Gary Pace appointed as a member of Immunicom’s Board of Directors. 

August

2016

Dr. Gary Pace, a seasoned bio-pharmaceutical executive with over 30 years of experience in the industry joins Immunicom's Board of Directors.

Immunicom enters an exclusive licensing agreement for University of California, San Diego for targeted molecule delivery technology.

December

2017

Immunicom enters an exclusive licensing agreement with University of California, San Diego for targeted molecule delivery technology

Immunicom successfully completes 300-treatment pre-clinical canine cancer trial

February

2016

The dogs in the trial were stage III or IV  patients  which  had  failed  standard  therapeutic  approaches. Overall,  50–60%  of  the  patients  treated  were  observed  to  have  either  stable  disease  or  partial  responses  by  RECIST Criteria during treatment with one patient having  experienced  a  complete  response  with  clearance  of  metastases.

Immunicom completes $5.5M Series A Preferred Stock financing

December

2015

Immunicom completes $5.5M Series A Preferred Stock financing.

Immunicom begins canine cancer pre-clinical trial

​

May

2014

Immunicom begins clinical trial in partnership with California Veterinary Specialists Angel Care Center and University of Pennsylvania School of Veterinary Medicine.

Immunicom signs strategic partnership agreement with Terumo BCT, a subsidiary of Terumo

January 2014

Terumo BCT is one of Japan's largest medical technology companies- an industry-leading specialist for  therapeutic apheresis machines that serves in more than 130 countries